News Releases and Corporate Updates

Our Blog

An ongoing series of informational entries

December 6, 2018

Ophthalmology researchers discuss the first in human phase 1/2 clinical study and data of DSP-Visulex.

Our Blog

An ongoing series of informational entries

March 7, 2018

Papangkorn and colleagues discuss drug transport kinetics and safety with respect to a wide variety of treatment modalities (treatment time duration and concentration/formulation) with DSP-Visulex.

Aciont Executives To Present and Participate at the 10th Ocular Diseases Drug Discovery Conference

March 8, 2018

Aciont will be one of three emerging companies showcased at the 10th Ocular Diseases Drug Discovery Conference organized by GTCbio is scheduled for March 20-21, 2018 in San Diego, CA. John Higuchi will be presenting Aciont's story on Day 2 of the event, March 21 around 12:55 PM. Dr. Balbir Brar will be participating during a special panel discussion on regulatory topics starting earlier in the day at 9:20 AM.

March 9, 2018

Dr. Kongnara Papangkorn, Aciont's Vice President of Product Development, will present findings from DSPV-201, a randomized, parallel group, double-masked, active controlled phase 1/2 clinical trial of dexamethasone sodium phosphate using the Visulex-P non invasive ocular drug delivery system.  See Kongnara's abstract

Our Blog

An ongoing series of informational entries

Aciont Presenting and Participating at Cross Border Investment Banking Conference in Hangzhou, China.

February 25, 2018

The conference is sponsored by B. Riley FBR, a preeminent U.S. based investment bank has partnered with TPP Healthcare, the top China business development firm, to bring you the largest gathering of healthcare centric companies and investors to date. They will be hosting 50+ Western healthcare companies (including Aciont Inc.) specializing in innovative technologies in areas that are vital to the growing Chinese healthcare industry, along with over 300+ Chinese healthcare strategic partners and investors.  Click here for information about this cross border investment banking conference

Archived News

An ongoing series of informational entries

December 2014

This article announced the enrollment of non infections anterior uveitis patients in DSPV-201, a randomized, parallel group, double-masked, active controlled phase 1/2 clinical trial of dexamethasone sodium phosphate using the Visulex-P non invasive ocular drug delivery system.

November 2017

John Higuchi presented a summary of Aciont's Visulex technologies at the OIS Conference in New Orleans, LA.

November 2017

DSP Visulex treatment modalities were tested in a pan uveitis model in rabbit.  The paper summarizes both efficacy and safety results in response to such DSP Visulex treatments.

Our Blog

An ongoing series of informational entries

May, 2013

Aciont received a second phase 2 SBIR grant (a phase 2b) to support the clinical development of DSP Visulex. Total funds from the National Eye Institute toward the support for DSP Visulex was about $4.4 million.